Rafael Holdings (RFL) Q4 2026 earnings review
Rafael Holdings files its lead drug, but cash runs low
Rafael Holdings, a developer of rare-disease drugs and medical devices, filed its lead drug for approval while its cash dwindled. Fourth-quarter operating losses narrowed to $10 million as the company cut overhead costs by more than half. However, cash dropped by $8 million in the quarter to $22 million, leaving less than three quarters of funding at that pace by our math.
| Cash and cash equivalents | $22.1M down $8.4M from last quarter |
|---|---|
| Operating loss | $9.7M $12.8M a year ago |
| Net loss per share | $0.18 $0.28 a year ago |
| Lead drug filing | Submitted FDA filing on October 28, 2026 |
⚖️ Verdict: 🔴 Bearish
The story got worse because the main Phase 3 study for remibetadex missed its primary goal in the overall patient group, and the cash balance fell to a tight level. While the company still submitted its FDA application in October using a positive subgroup analysis, it now faces regulatory uncertainty alongside a going-concern warning.
The question now is whether the FDA will accept and approve an application based on subgroup data and external survival comparisons before cash runs out. If regulators accept the filing and grant a priority review voucher, the company gains a path to cash; if they refuse to file it, the business lacks the funds for another long trial. The FDA's filing acceptance decision in the next two months will tell.
🐂 Bull Case
Lead Drug Application Filed Despite Trial Miss
Rafael Holdings develops experimental medicines, led by remibetadex, a treatment for Niemann-Pick Disease Type C, a fatal genetic disorder. On October 28, its subsidiary Cyclo Therapeutics asked US regulators to approve the drug. Although the main study failed overall, it "showed 71% slowing of disease progression in a prespecified analysis of patients receiving background miglustat and/or leucine therapy (p=0.046)", the company said.
The biotechnology group also backed the filing with data comparing patient survival against an external registry. In addition, the application asks for "a rare pediatric disease priority review voucher", Rafael Holdings said. Drugmakers can sell these vouchers to other pharmaceutical companies for cash, so an approval could bring in money alongside product sales.
What to watch: the Food and Drug Administration's decision on whether to accept the application for review, which usually arrives within 60 days of filing. Acceptance would mean regulators are willing to review the subgroup data despite the overall study miss.
Lower Overhead Costs Narrowed the Quarterly Loss
Rafael Holdings cut its overhead spending in the fourth quarter, which narrowed its operating loss to $9.7 million from $12.8 million a year ago. General and administrative expenses, which cover staff and office overhead, dropped 55.5% to $2.4 million, or by 569 percentage points of revenue by our math.
The drug developer attributed the savings to "a decrease in payroll, stock-based compensation expense and professional fees". Full-year administrative costs fell by $4.1 million to $9.7 million because prior-year merger fees did not repeat and the business terminated staff. Research spending stayed at $7.5 million in the quarter, up 904 percentage points of revenue by our math as sales shrank.
What to watch: quarterly research and development expenses in the first quarter of fiscal 2027. With the main Phase 3 trial completed in June 2026, research costs should fall from the $7.5 million fourth-quarter level.
🐻 Bear Case
Cash Drop Leaves Under Three Quarters Left
Rafael Holdings finished the fiscal year in July with $22.1 million in cash, down from $30.5 million three months earlier and $52.8 million a year ago. In the release, the biotechnology group cited "the substantial doubt about our ability to continue as a going concern" and its need for additional financing.
- Fourth-quarter cash drop: $8.4 million by our math, the largest quarterly decline of the year
- Full-year cash drop: $30.7 million, or 58.2% of starting cash by our math
- Cash left at the fourth-quarter pace: 2.6 quarters by our math
That cash drain matters because a regulatory review takes months, even with priority status, and launching a drug requires commercial spending. Unless research costs drop sharply now that the Phase 3 trial is over, the business will need to raise money before the regulator makes a final decision on remibetadex.
What to watch: cash and cash equivalents in the first-quarter report, alongside any new financing announcements. A quarterly cash drop above $5 million would leave the group with less than a year of funding during the FDA review.
Phase 3 Miss Clouded the Approval Path
Rafael Holdings wants to become a commercial drugmaker through remibetadex, and it submitted its drug application to the FDA in October. However, the pivotal Phase 3 TransportNPC study "did not meet its primary endpoint in the overall population (p=0.19)", the company said.
A p-value of 0.19 is well above the 0.05 threshold regulators normally require to prove a drug works. The drug developer is relying on a subgroup of patients on background therapy where the p-value was 0.046, just inside the threshold. Rafael Holdings warned in the release that the FDA may refuse to accept or approve the filing because the overall study missed its goal.
What to watch: whether the FDA accepts the filing and grants priority review. A refusal-to-file letter would require new clinical work that the current $22.1 million cash balance cannot fund.
Debt Settlements Masked Higher Full-Year Losses
Rafael Holdings reported that its full-year net loss narrowed to $29.6 million from $30.5 million in fiscal 2025. That improvement came from accounting gains rather than operations, because full-year operating losses actually widened to $33.4 million from $29.2 million after consolidating Cyclo Therapeutics for a full year.
The bottom line benefited from a $4.4 million gain on settling accounts payable and convertible notes at its Cornerstone subsidiary, including $464 thousand in the fourth quarter. Excluding those one-off settlement gains, the full-year net loss was $34.1 million and the fourth-quarter net loss was $9.6 million by our math.
What to watch: operating loss in the first quarter of fiscal 2027. With non-current convertible notes down to $2 thousand on the balance sheet, settlement gains will no longer cushion the bottom line.
👓 Other Themes
New Trials Expand the Early Pipeline
Alongside its Niemann-Pick filing, Rafael Holdings added two early-stage drug programs during the second half of fiscal 2026. In April, Cyclo signed an "exclusive, worldwide license with the Massachusetts Institute of Technology" to test its cyclodextrin compound in Alzheimer's disease, the company said. In June, LipoMedix started an investigator-led Phase II trial in Israel testing Promitil with radiotherapy "in patients with cisplatin-ineligible head and neck cancer".
💲 Other KPIs
Fourth-quarter revenue fell 30.3% from a year ago, but rose 36.3% from the third quarter's $179 thousand. Full-year sales were $874 thousand, down 4.7% from $917 thousand. The company generates small product and property rental revenues while building a "regional distributor network" for its VECTR orthopedic device system.
Weighted average shares rose 19.9% from a year ago in the fourth quarter, and 74.7% for the full year, after the company issued stock to buy Cyclo Therapeutics in March 2025 and completed a rights offering in June 2025. The higher share count cut the full-year loss per share to $0.58 from $1.04.
Current and non-current prepaid clinical costs — upfront payments for medical studies not yet expensed — fell 27.4% from $3.16 million in the third quarter by our math. The balance declined as Cyclo completed the Phase 3 TransportNPC study in June 2026.
❓ Key Questions
How much will quarterly cash burn fall after TransportNPC?
Research spending jumped back to $7.5 million in the fourth quarter as the Phase 3 study wrapped up in June. Investors need to know the ongoing quarterly spending rate now that the trial is finished and the application is filed.
Did the FDA support filing on the subgroup analysis?
The TransportNPC study missed its main goal in the overall patient group (p=0.19) and succeeded only in a subgroup on background therapy (p=0.046). Management has not disclosed what the FDA said in pre-submission meetings about filing on that subgroup.
How will Rafael Holdings fund operations beyond early 2027?
With $22.1 million in cash and an $8.4 million fourth-quarter cash drain, the company noted substantial doubt about continuing as a going concern. Management has not said whether it plans another rights offering, asset sales, or partnering deals.
What are the fourth-quarter sales for the VECTR system?
The company highlighted the commercial rollout of its FDA-cleared VECTR orthopedic device system, but the earnings release did not break out product revenue versus rental revenue for the fourth quarter.